Cervical Adenosquamous Carcinoma
39
3
9
24
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
17 trials with published results (44%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
7.7%
3 terminated out of 39 trials
88.9%
+2.4% vs benchmark
15%
6 trials in Phase 3/4
71%
17 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (39)
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
RT for Adenocarcinoma/Adenosquamous Carcinoma
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
Hybrid PET/MR in the Therapy of Cervical Cancer
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer